Trial Profile
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer With and Without Intra-operative RT: a Window of Opportunity Study
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms Pembro/IORT
- 10 Oct 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 18 Aug 2021 Planned End Date changed from 1 Dec 2021 to 31 Dec 2024.
- 18 Aug 2021 Planned primary completion date changed from 1 Dec 2020 to 31 Dec 2022.